Skip to content
The Nexus
HEALTHJul 1 · 18:28 UTCMEDPAGE TODAY

More Early Breast Cancer Patients Could Be Spared Chemo, Trial Suggests

The OPTIMA trial suggests genomic testing could identify more hormone receptor-positive/HER2-negative early breast cancer patients who might avoid chemotherapy. Results were presented at the American Society of Clinical Oncology (ASCO) meeting.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
OPTIMA trialtopicAmerican Society of Clinical Oncologyorganizationhormone receptor-positive/HER2-negative early breast cancertopicgenomic testingtopicchemotherapytopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting